Fig. 5From: Consumption and cost trends of EGFR TKIs: influences of reimbursement and national price negotiationMonthly DDDs of Gefitinib, Erlotinib and Icotinib form January 2016 to December 2019. A Monthly DDDs of Gefitinib form January 2016 to December 2019; (B) Monthly DDDs of Erlotinib form January 2016 to December 2019; (C) Monthly DDDs of Icotinib form January 2016 to December 2019. DDDs, defined daily dosesBack to article page